导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.72% | 2011/4773 |
| 近一周 | -0.06% | 903/5465 |
| 近一月 | 5.03% | 71/5421 |
| 近一季 | 5.65% | 308/5231 |
| 近半年 | 4.87% | 841/4920 |
| 近一年 | 3.30% | 2098/4394 |
| 近两年 | 37.25% | 2022/2954 |
| 近三年 | 45.59% | 646/2253 |
| 成立以来 | 55.39% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.72% 2878/4961 |
-8.21% 3858/5312 |
- - |
- - |
| 2025 | 9.68% 2856/4813 |
2.36% 1396/3635 |
11.27% 195/4076 |
-8.49% 4041/4524 |
5.23% 460/4813 |
| 2024 | 38.47% 39/3463 |
9.85% 107/2808 |
6.75% 137/3014 |
12.10% 2415/3129 |
5.34% 615/3463 |
| 2023 | -3.13% 628/2656 |
-2.55% 2013/2280 |
1.41% 218/2385 |
4.65% 140/2515 |
-6.33% 1722/2655 |
| 2022 | -4.78% 106/2207 |
2.21% 70/1919 |
-1.50% 1731/2016 |
-8.39% 196/2113 |
3.24% 742/2208 |
| 2021 | -1.72% 816/1822 |
9.84% 53/1255 |
-2.69% 1225/1330 |
-7.30% 1040/1466 |
-0.81% 1277/1822 |
| 2020 | 0.51% 938/1250 |
-13.63% 934/1028 |
2.09% 978/1067 |
4.73% 944/1164 |
8.83% 657/1184 |
| 2019 | 24.40% 618/1092 |
15.23% 692/739 |
2.29% 89/788 |
-0.78% 616/850 |
6.36% 620/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华宝中证银行ETF联接C VS. 长安沪深300非周期A(740101) |